Ann Vasc Med | Volume 2, Issue 1 | Review Article | Open Access

Rivaroxaban in Venous Pulmonary Thromboembolism

Adem Dirican1, Ali Ekber Atas2, Tugce Uzar3, Pankina Ekaterina4 and Sevket Ozkaya3*

1Department of Pulmonary Medicine, Samsun Medicalpark Hospital, Turkey
2Department of Cardiology, Samsun Medicalpark Hospital, Turkey
3Department of PulmonaryMedicine, Bahcesehir University, Turkey4Department of PulmonaryMedicine, Bashkir State Medical University, Turkey

*Correspondance to: Sevket Ozkaya 

Fulltext PDF


Background: With the advent of new oral anticoagulants for the treatment of deep-vein thrombosis and/or pulmonary embolism, a new era of oral anticoagulation for patients with venous thromboembolism has begun. Rivaroxaban is the first new oral anticoagulant to receive regulatory approval for the acute and continued treatment of deep-vein thrombosis and pulmonary embolism.
Methods: We aimed to investigate the effects of rivaroxaban in patients with pulmonary embolism.
Results: The ages of patients are varies between 34-84 years old and male/female ratio was 14/8. The average length of ICU(─░ntensive Care Unit) and hospital stays are 69.5 hours and 6 days, respectively. The treatment complications were seen in only two patients including nausea and minor gastrointestinal hemorrage. Rivaroxaban treatment was stopped in patients with hemorrhage. There was no any major bleeding and reccurence or treatment failure. Conclus─▒ons: We think that the enoxaparin followed by rivaroxaban is effective, safe for long-term treatment in patients with pulmonary embolism. Also, rivaroxaban treatment doesn’t require laboratory coagulation monitoring.


Pulmonary embolism; New oral anticoagulants; Rivaroxaban


Dirican A, Atas AE, Uzar T, Ekaterina P, Ozkaya S. Rivaroxaban in Venous Pulmonary Thromboembolism. Ann Vasc Med. 2019;2(1):1008.

Subscribe to Our Newsletter